Ampion™ for Inflammation

Ampion™ for Inflammation

Ampion™ for Inflammation


Ampion™ is an NME being developed as a non-steroidal injection and oral drug for the treatment of diseases involving inflammation. As a mimic of a naturally occurring human molecule, Ampion™ is predicted to have an excellent human safety profile. Ampion™ selectively reduced inflammatory and immune responses in a variety of in vitro and ex vivo investigations that included human cells and tissue. Oral Ampion™ significantly reduced neurological symptoms without toxicity in an in vivo model of inflammatory and immune-mediated CNS disease. Ampion™ appears to be suitable for the treatment of a variety of chronic inflammatory and immune-mediated diseases including arthritis, allergic conjunctivitis and rhinitis, inflammatory respiratory diseases and neurodegenerative CNS diseases.




« back to products page

Learn More About:

Premature Ejaculation (PE)

Premature ejaculation is a distressing male sexual dysfunction that is more common than erectile dysfunction (ED) and has a major impact on the quality of life for men and their sexual partners.

Diabetic Retinopathy

A complication of diabetes mellitus that damages the retina in the eyes and leads to blindness

Diabetic Nephropathy

A progressive complication of diabetes mellitus that leads to end-stage renal disease (ESRD) requiring kidney transplantation or chronic dialysis

AMPE Stock Quote - delayed
Last Change
AMPE 5.08

Ampio News

05/13/2013 | Press Release

Ampio Pharmaceuticals Announces Participation at the UBS Global Healthcare Conference

04/25/2013 | Press Release

Ampio Pharmaceuticals Completes Enrollment in Run-In SPRING study of Ampion™ in Osteoarthritis of the Knee

04/02/2013 | Press Release

Ampio Receives FDA Clearance to Initiate Clinical Trial of Ampion™ for the Treatment of Osteoarthritis of the Knee: Patient Treatments have begun.

» See all Ampio news